Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Biological: bevacizumab
Drug: cisplatin
Drug: irinotecan hydrochloride
Genetic: proteomic profiling
Other: diagnostic laboratory biomarker analysis
Other: mass spectrometry
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Radiation: radiation therapy

First Posted Date: 2006-07-20

Last Posted Date: 2016-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 34

Registration Number: NCT00354679

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: leucovorin calcium
Procedure: conventional surgery
Radiation: radiation therapy
Drug: oxaliplatin
Other: laboratory biomarker analysis
Genetic: DNA analysis
Genetic: polymerase chain reaction
Other: immunohistochemistry staining method

First Posted Date: 2006-06-12

Last Posted Date: 2025-01-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 248

Registration Number: NCT00335816

Locations: 🇺🇸
Cancer Care Center at John Muir Health - Concord Campus, Concord, California, United States
🇺🇸
St. Joseph Hospital Regional Cancer Center - Orange, Orange, California, United States
🇺🇸
Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia, United States

and more 12 locations

A Randomized Study of Sulindac in Oral Premalignant Lesions

Not Applicable

Completed

Conditions: Leukoplakia, Oral
Benign Neoplasms

Interventions: Drug: sulindac
Drug: Placebo

First Posted Date: 2006-03-06

Last Posted Date: 2020-11-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 63

Registration Number: NCT00299195

Locations: 🇮🇳
Amrita Institute of Sciences (AIMS), Cochin, India
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇮🇳
Regional Cancer Center (RCC), Trivandrum, India

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: rituximab
Drug: bortezomib
Drug: cyclophosphamide
Drug: prednisone

First Posted Date: 2006-02-24

Last Posted Date: 2018-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 79

Registration Number: NCT00295932

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 5 locations

Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2005-12-01

Last Posted Date: 2007-01-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT00260026

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Targretin® (bexarotene)
Drug: pegylated liposomal doxorubicin hydrochloride

First Posted Date: 2005-11-21

Last Posted Date: 2018-08-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT00255801

Locations: 🇺🇸
Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
NYU Cancer Institute at New York University Medical Center, New York, New York, United States

and more 2 locations

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carboplatin
Drug: etoposide
Drug: ifosfamide

First Posted Date: 2005-11-21

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 98

Registration Number: NCT00255723

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2005-11-09

Last Posted Date: 2008-04-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT00250978

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

Not Applicable

Active, not recruiting

Conditions: Colorectal Neoplasms
COlorectal Carcinoma
Colorectal Cancer
Colorectal Tumor

Interventions: Drug: Iodine-124 labeled humanized A33 (antibody)

First Posted Date: 2005-09-20

Last Posted Date: 2025-05-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00199862

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Drug: Raloxifene followed by combination therapy
Drug: Exemestane followed by combination therapy

First Posted Date: 2005-09-20

Last Posted Date: 2023-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT00200174

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy